70 articles, transcripts, and reports
Abbott Laboratories (NYSE: ABT) reported second quarter 2023 earnings results today. Net sales decreased 11.4% year-over-year to $10 billion. Organic sales growth, excluding COVID-19 tests, was…
Abbott Laboratories (NYSE: ABT) Q1 2023 earnings call dated Apr. 19, 2023 Corporate Participants: Scott Leinenweber — Vice President, Investor Relations, Licensing and Acquisitions Robert Ford — Chairman and…
Abbott Laboratories (NYSE: ABT) has contributed significantly to COVID care activities by providing test kits, and the healthcare conglomerate’s revenues benefitted from that in recent…
Abbott Laboratories (NYSE:ABT) Q4 2022 Earnings Call dated Jan. 25, 2023. Corporate Participants: Scott Leinenweber — Vice President of Investor Relations, Licensing, and Acquisition Robert Ford — Chairman and…
Abbott Laboratories (NYSE: ABT) reported fourth quarter 2022 earnings results today. Net sales declined 12% year-over-year to $10.1 billion. Net earnings decreased 48% to $1…
Abbott (NYSE: ABT) Q3 2022 earnings call dated Oct. 19, 2022 Corporate Participants: Scott Leinenweber — Vice President of Investor Relations, Licensing, and Acquisition Robert Ford — Chairman and…
Abbott (NYSE: ABT) reported third quarter 2022 earnings results today. Sales decreased 4.7% year-over-year to $10.4 billion. On an organic basis, sales increased 1.3%. Net…
Abbott (NYSE: ABT) Q3 2022 Earnings Conference
Abbott (NYSE: ABT) Q2 2022 earnings call dated Jul. 20, 2022 Corporate Participants: Scott Leinenweber — Vice President, Investor Relations, Licensing and Acquisitions Robert B. Ford — Chairman and…
Abbott Laboratories (NYSE: ABT) reported second quarter 2022 earnings results. Total sales increased 10.1% year-over-year to $11.3 billion. On an organic basis, revenues grew 14.3%.…
